Ketoconazole, vaginal suppositories 400 mg 10 pcs

The active ingredient is ketoconazole, a derivative of imidazoldioxolane.

It has fungicidal and fungostatic action against dermatophytes (Trichophyton spp., Epidermophyton floccosum, Microsporum spp.) and yeast fungi (Pityrosporum spp., Candida spp. (including Candida albicans).

The mechanism of action is inhibition of ergosterol biosynthesis and changing lipid composition of the membrane of fungi.

The drug is active against staphylococci and streptococci.

Indications

Treatment of acute and chronic recurrent vaginal mycosis.

The prevention of fungal infections of the vagina with low resistance of the body and against the background of treatment with antibiotics and other drugs that disrupt the normal vaginal flora.

Active ingredient

Composition

1 suppository contains:

the active ingredient:

ketoconazole 400 mg;

auxiliary substances:

butylhydroxyanisole 0.5 mg,

semisynthetic glycerides (Supocir AM) – enough to make a suppository weight of 2000 mg.

How to take, the dosage

The drug is used intravaginally, i.e. inserted into the vagina.

To remove the suppository from the cell pack, break off one suppository cell along the notch and pull the edges of the band apart. Insert the suppository into the vagina with the pointed end, as deeply as possible.

For the prevention of fungal lesions, use suppositories at a dose of 200 mg once daily for 10 days.

To treat thrush, use suppositories in a dose of 200 mg twice daily or suppositories in a dose of 400 mg once daily for 3 days.

In case of genital mycosis and acute and chronic vaginal candidiasis, suppositories in a dose of 200 mg twice a day or suppositories in a dose of 400 mg once a day for 5 days.

If necessary, the tablets (oral) and suppositories (intravaginal) may be combined.

Interaction

Concomitant use with rifampicin and isoniazid decreases the plasma concentration of ketoconazole. In concomitant use with cyclosporine, indirect anticoagulants and methylprednisolone ketoconazole may increase the plasma concentration of the latter.

Ethanol and other hepatotoxic drugs increase the risk of hepatic parenchyma. Increases the concentration of sulfonylurea derivatives and increases the risk of hypoglycemia.

Limits the effect of amphotericin B. Increases plasma concentrations of digoxin, midazolam and triazolam. Increases the bioavailability of indinavir.

Decreases the stimulatory effect of corticotropin on the adrenal glands. When combined with terfenadine, astemizole and cisapride, increases the risk of severe ventricular tachycardia, including pirouette type.

Induces the risk of breakthrough bleeding when using low hormone oral contraceptives at one time. Increases the toxicity of phenytoin.

Special Instructions

During treatment, the peripheral blood count and the functional status of the liver and kidneys should be monitored regularly.

Contact with latex products (contraceptive diaphragms, condoms should be avoided.

Contraindications

Hypersensitivity to the components of the drug, pregnancy, lactation.

Side effects

Hyperemia and irritation of the vaginal mucosa, vaginal itching.

Allergic reactions: skin rash, urticaria.

Overdose

Because of the low absorption of the drug when used intravaginally in the recommended (therapeutic) doses, overdose is unlikely.

Inadvertent ingestion may cause poisoning symptoms.

There is no specific antidote.

If necessary, take activated charcoal and conduct symptomatic treatment.

Similarities